Orion Pharma Secures Exclusive European Rights to Qilu's Pembrolizumab Biosimilar
OEC sits 35% above its 52-week low of $4.345.
Summary
Orion Pharma has signed an agreement with Qilu Pharma Europe to commercialize an intravenous pembrolizumab biosimilar across Europe. Orion gains exclusive distribution, marketing, and sales rights, while Qilu supplies the product and receives a profit share plus development, regulatory, and sales milestone payments. This expands Orion's oncology portfolio and builds on its existing partnership with Qilu. The deal aligns with the company's stated goal of broadening access to affordable medicines. No financial terms were disclosed, but the exclusive European rights represent a meaningful commercial opportunity in the biosimilar oncology space.
At the time of this announcement, OEC was trading at $5.85 on NYSE in the Life Sciences sector, with a market capitalization of approximately $330.7M. The 52-week trading range was $4.35 to $8.64. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.